Search results for " Europe"

Article Biopharma in 2016: Higher Quality Drugs, Less Expensive Manufacturing
In contrast, Zarxio has been available in Europe since 2006. There are more than 700 biosimilars approved or in the pipeline globally. Analysts expect the worldwide biosimilars market to reach $25 bil…

Article Managing Risk in Raw Material Sourcing
The company has established sites in the United States, Europe, and India, based on customer demand for local materials. For Avantor’s offshore suppliers, he adds, the use of (local) advisors helps en…

Article Biosimilars to Drive Modern Manufacturing Approaches
Concerns about adverse events have diminished as biosimilar use has expanded in Europe. As more competitors enter biosimilar markets, Gal expects discounts will rise from the 30% range to more than 75…

Article A Q&A with Eric Langer: CMOs Embrace New Technology
The trends in the US appear to be slightly more aggressive than in Europe. What was the most surprising trend revealed in the 13th Annual Report and Survey of BioManufacturing? Why? The biop…

Article Managing Biomanufacturing Capacity Expectations
In Europe, because physicians seem to be more accepting of biosimilars, market penetration forecasts may be a bit more clear—but in the United States, physician acceptance and prescribing practices (a…

Article An Integrated Approach to Ensure the Viral Safety of Biotherapeutics
Testing product and process intermediates alone is helpful, but does not provide a complete solution to viral safety. This article proposes integrated solutions for systemic and proactive viral risk m…

Article Optimizing Cation-Exchange Chromatography with High-Throughput Process Development for mAb Purification
Since the first therapeutic antibody came onto the market in 1986, up to the end of 2014, 47 products have been approved in the United States or Europe for a number of diseases including various types…

Article Breakthrough Drugs Raise Development and Production Challenges
The time reduction presents “significant challenges to the development team,” he commented, and may be further complicated if the firm seeks to file simultaneous applications in Europe, Japan, and eme…

Article Taking a “Development-by-Design” Approach to Cell Therapies
Invetech has been working on cell therapy process scale-up automation for more than 10 years and has successfully completed projects in North America, Europe, and Asia for companies that include Argos…

Article Biopharma Advances Demand Specialized Expertise
Roundtable participants are Gary Chambers, business manager biopharma labs, Europe, SGS; Bill Hartzel, director of strategic execution, Catalent Pharma Solutions; Chris R. Lively, PhD, director of bio…

Previous PageNext Page